Sam K. Saha: Same Clot Against Fast and Slow Systems
Sam K. Saha, VP of Medical Operations and Technology at Sevaro, shared on LinkedIn:
”2 patients arrived at 2 different ERs at the exact same time, same age and symptoms.
Only one walked out of the hospital.
Here’s what made the difference.
Patient A went to a traditional hospital.
The stroke activation was delayed, the CT was backed up, and the nurses were busy with patients who seemed sicker.
Door-to-needle time: 75 minutes.
The patient left for rehab with dense right-sided paralysis.
Patient B went to a resource-limited site with a hyper-integrated telestroke workflow.
The neurologist was already on the screen while the patient was still on the CT table.
Door-to-needle time: 15 minutes.
The patient walked out 48 hours later.
Same clot, same drug, sixty minutes of difference.
Two completely different lives.
Both teams knew exactly what to do. The difference came down to how fast the system let them do it.
Time is neurons, and the truth is, the system determines how much time you have.
Resource-limited doesn’t have to mean outcome-limited.
With proper workflow design, telestroke can thrive anywhere.”
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal